Advanced Filters
noise

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 3,040 clinical trials
S Stefano Ghirardello, MD

Early Prediction of Lung Injury in Preterm Infants Score

The main hypothesis is that even preterm infants considered "stable" receiving non-invasive ventilation may be at risk of developing BPD due to an inhomogeneous distribution of ventilation. Identifying this characteristic from the first days of life by using EIT could, in the future, optimize non-invasive ventilation strategies as early as …

26 - 32 years of age All Phase N/A
D Duc M Ha, MD MAS

Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer

Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, …

18 years of age All Phase N/A
F FREDERIC BIGOT, MD

Clinico-biological Data Collection Study of Metastatic Lung Cancer

RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective …

18 years of age All Phase N/A
C Christiane De Boeck, MD, Phd

Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia (PCD) is a rare disease, caused by impairment of the motile cilia. Patients present with chronic upper and lower respiratory tract infections. The therapy is mainly supportive and based on that of cystic fibrosis. Chest physiotherapy is one of the cornerstones of the therapy, however the influence …

6 - 50 years of age All Phase N/A
S Slavisa Tubin, MD

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky …

18 years of age All Phase N/A
L Luca Bertolaccini

Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site

investigate the molecular differences between primitive lung cancer and the metastatic site.

18 years of age All Phase N/A
G Güldeniz Argun, M.D.

Comparison of FCV and VCV in One-Lung Ventilation

One-lung ventilation (OLV) is commonly used during thoracic surgery but may negatively affect lung mechanics and gas exchange. Different ventilation strategies are used during OLV, and their effects on respiratory parameters remain an important clinical concern. Flow-controlled ventilation (FCV) is a newer ventilation mode that allows precise control of inspiratory …

18 - 80 years of age All Phase N/A
F FEN WANG

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.

18 years of age All Phase N/A
S Site Public Contact

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the …

18 years of age All Phase 2
C Cindy Jin

Feasibility of Reducing Respiratory Drive Using the Through-flow System

Mechanical ventilation can lead to diaphragm and lung injury. During mechanical ventilation, the diaphragm could be completely rested or it could be overworked, either of which may cause diaphragm injury. Mechanical stress and strain applied by mechanical ventilation or by the patient's own respiratory muscles can also cause injury to …

18 years of age All Phase N/A

Simplify language using AI